|
Post by dreamboatcruise on Apr 11, 2018 16:09:39 GMT -5
I don't know what the heck you are talking. 30 Mar 2018 Afrezza----519 $577k 277 $321k Apidra----6693 $5.16m 2499 $2.03m Novalog--137k $133m 56.3k $58.5m Humalog-155k $144m 60.8k $59.7m Humalin--37.9k $20.6m 14.8k $7.9m I'm aware of that. Mike, as I recall, said that they had taken 1% of the market in some "territories." How does one find out the sales of humalog/apidra/novolog in those specific territories. Without knowing those, how can anyone claim they've taken 1% of the market in any given territory? Regardless, I want the real numbers, not percentages. Also, I still cannot find the "The Diabetes Forum: Automated Insulin Delivery” report referred to in the slides -- does anyone recognize it or know where to get a copy? That data is available from Symphony and IMS. Apparently it is only the aggregate data for the entire country that is available via Bloomberg. For the rest one need go directly to the source and pay for the data.
|
|
|
Post by od on Apr 11, 2018 16:38:17 GMT -5
I'm aware of that. Mike, as I recall, said that they had taken 1% of the market in some "territories." How does one find out the sales of humalog/apidra/novolog in those specific territories. Without knowing those, how can anyone claim they've taken 1% of the market in any given territory? Regardless, I want the real numbers, not percentages. Also, I still cannot find the "The Diabetes Forum: Automated Insulin Delivery” report referred to in the slides -- does anyone recognize it or know where to get a copy? That data is available from Symphony and IMS. Apparently it is only the aggregate data for the entire country that is available via Bloomberg. For the rest one need go directly to the source and pay for the data. ...and, I believe, Symphony and IMS can provide individual provider prescribing counts for each product.
|
|